A two-year follow-up cohort study from Norway reported higher rates of sustained remission as well as lesser progression of angiographic lesions in patients receiving anti-TNF-α agents, when compared with conventional treatments in Takayasu’s arteritis [47]. The gene discussed is TNF; the disease is Takayasu arteritis.